Revlimid and Imnovid Triple Combos Approved in EU for Adults with Multiple Myeloma
The European Commission has approved two combination therapies…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Takeda Oncology Launches Myeloma Patient and Caregiver Mentorship Support Program
Takeda Oncology has launched a mentorship program aimed…
Phase 3 Trial of Immune System-targeting Treatment for Advanced Multiple Myeloma Begins Dosing
A pivotal Phase 3 clinical trial has begun dosing…
OncLive Poised to Induct 2019 Class of ‘Giants of Cancer Care’
OncLive, a digital resource platform for oncologists, will welcome 15…
Allogene’s CAR T-cell Therapy Triggers Durable Anti-Tumor Response in Animal Model
ALLO-715, Allogene Therapeutics‘ donor-derived CAR T-cell therapy, can…
Kyprolis Combo Shows Promise for Newly Diagnosed, Transplant-eligible Patients
A triple regimen composed of Kyprolis (carfilzomib),…
